-
Mashup Score: 1
Nerea Lopetegui-Lia, MD, discusses fertility preservation options for patients with TNBC and considerations for managing treatment-related toxicities.
Source: www.onclive.comCategories: General Medicine NewsTweet
-
Mashup Score: 5Novel Adjuvant Strategies Reshape HER2+ Breast Cancer Treatment - 2 hour(s) ago
Paolo Tarantino, MD, discusses adjuvant strategies, trial data, and risk stratification shaping HER2+ breast cancer care.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Novel Adjuvant Strategies Reshape HER2+ Breast Cancer Treatment @PTarantinoMD @DanaFarberNews #BreastCancer https://t.co/KUzAMt3iuI
-
-
Mashup Score: 5Renowned breast cancer physician-scientist Hope S. Rugo, M.D., to lead City of Hope’s Women’s Cancers Program - 3 hour(s) ago
Dr. Rugo has led key breast cancer therapy trials and exudes a passion for serving patients
Source: www.onclive.comCategories: General Medicine NewsTweet-
Renowned Breast Cancer Physician-Scientist Hope S. Rugo, MD, to Lead City of Hope's Women’s Cancers Program @hoperugo @cityofhope #bcsm https://t.co/4Anr9ipx3B
-
-
Mashup Score: 4
China’s NMPA has accepted an sNDA for review, seeking the approval of repotrectinib for advanced solid tumors harboring NTRK fusions.
Source: www.onclive.comCategories: General Medicine NewsTweet-
China’s NMPA Accepts sNDA for Repotrectinib for NTRK+ Solid Tumors #oncology https://t.co/M5FbMjqe6o
-
-
Mashup Score: 5
The combination of sacituzumab govitecan and pembrolizumab improved PFS vs pembrolizumab plus chemotherapy in PD-L1–positive mTNBC.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1–Positive mTNBC #BCSM #oncology https://t.co/FzrYFTtcXz
-
-
Mashup Score: 8
Frontline T-DXd plus pertuzumab led to statistically significant and clinically meaningful PFS improvements vs THP in HER2+ metastatic breast cancer.
Source: www.onclive.comCategories: General Medicine NewsTweet-
T-DXd/Pertuzumab Yields PFS Benefit vs THP in HER2+ Metastatic Breast Cancer #BCSM #oncology https://t.co/J1umNYN2uR
-
-
Mashup Score: 3Broader ARPI Arsenal Enables Personalized, Cost-Conscious Treatment Selection in Prostate Cancer - 7 hour(s) ago
Nataliya Mar, MD, discusses clinical considerations when selecting between the wide range of androgen receptor pathway inhibitors in prostate cancer.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Broader ARPI Arsenal Enables Personalized, Cost-Conscious Treatment Selection in Prostate Cancer @mar_nataliya @UCIrvineHealth #pcsm #oncology https://t.co/rWyM6Mrk5t
-
-
Mashup Score: 4Biomarker Research Aims to Overcome Treatment Challenges in Squamous Cell Carcinoma of the Lung - 9 hour(s) ago
Fawzi F Abu Rous, MD, discusses ongoing efforts to address unmet needs in the management of squamous cell carcinoma of the lung.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Biomarker Research Aims to Overcome Treatment Challenges in Squamous Cell Carcinoma of the Lung @FawziAbuRous @HenryFordHealth @HopkinsMedicine #lcsm #oncology https://t.co/zop8s9UV6r
-
-
Mashup Score: 8
Acimtamig plus AlloNK was associated with high objective response rates in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma.
Source: www.onclive.comCategories: General Medicine NewsTweet-
At a data cutoff of November 14, 2024, among all 4 cohorts of patients with heavily pretreated R/R Hodgkin #lymphoma, the ORR was 86%, including 12 complete responses and 12 partial responses, following treatment of acimtamig plus AlloNK. #EMBT2025 https://t.co/8I3cgI26xV
-
-
Mashup Score: 7Apraglutide/Ruxolitinib Provides Efficacy Benefit vs Ruxolitinib Alone in Refractory GI aGVHD - 12 hour(s) ago
A comparative analysis showed that apraglutide plus ruxolitinib improved response rates vs ruxolitinib monotherapy in steroid-refractory GI aGVHD.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Apraglutide/ruxolitinib showed improved short- and long-term efficacy outcomes vs ruxolitinib alone in patients with steroid-refractory GI acute #GVHD, according to findings from a study comparing efficacy outcomes from 2 trials. Read up on the comparison: https://t.co/feJn3s4qnU https://t.co/Evd6Qy327N
-
Fertility and Toxicity Considerations Factor into TNBC Management @nerealiamd @OSUCCC_James #bcsm #oncology https://t.co/5Sfw1JBJNv